ATR抑制剂BAY 1895344作为头颈部鳞状细胞癌放射增敏剂的临床前评估
在HPV阴性头颈部鳞状细胞癌细胞系(MOC2、MOC1、JHU-012)及小鼠移植瘤模型中评估ATR抑制剂BAY 1895344的放射增敏作用。结果显示BAY 1895344在体外和体内均增加放射敏感性,作者认为具有治疗潜力,值得在局部晚期或复发HPV阴性HNSCC患者中开展临床试验评估。
要点
- ATR抑制剂BAY 1895344在HPV阴性HNSCC细胞系中产生放射增敏作用。
- BAY 1895344联合放疗在MOC2和JHU-012小鼠模型中显著延迟肿瘤生长。
- MOC2模型中联合治疗改善总生存;作者认为值得临床试验评估。
核心结论
- BAY 1895344在HPV阴性HNSCC临床前模型中增加体外和体内放射敏感性,提示具有治疗潜力,值得在局部晚期或复发HPV阴性HNSCC患者中开展临床试验评估。
研究设计与样本
- 临床前研究:使用小鼠和人HPV阴性HNSCC细胞(MOC2、MOC1、JHU-012)及永生化小鼠口腔角质细胞,以及携带MOC2或JHU-012移植瘤的小鼠。
主要发现
- 放疗(4 Gy)后1小时,ATRi剂量依赖性降低检查点激酶1磷酸化;放疗后18小时,ATRi剂量依赖性增加γH2AX。
- 加入放疗使HNSCC细胞系中BAY 1895344的半数抑制浓度降低,但永生化小鼠口腔角质细胞中未降低。
- 克隆形成实验显示HNSCC细胞系中发生放射增敏。
- ATRi消除放疗诱导的G2/M检查点,导致有未修复DNA损伤的有丝分裂及有丝分裂异常增加(多核细胞、微核、核芽、核质桥)。
- 在MOC2和JHU-012体内模型中,ATRi联合放疗显著延迟肿瘤生长,MOC2模型中改善总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite aggressive multimodal treatment that typically includes definitive or adjuvant radiation therapy (RT), locoregional recurrence rates approach 50% for patients with locally advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). Thus, more effective therapeutics are needed to improve patient outcomes. We evaluated the radiosensitizing effects of ataxia telangiectasia and RAD3-related (ATR) inhibitor (ATRi) BAY 1895344 in preclinical models of HNSCC. METHODS AND MATERIALS: Murine and human HPV-negative HNSCC cells (MOC2, MOC1, JHU-012) were treated with vehicle or ATRi with or without 4 Gy. Checkpoint kinase 1 phosphorylation and DNA damage (γH2AX) were evaluated by Western blot, and ATRi half-maximal inhibitory concentration was determined by MTT assay for HNSCC cells and immortalized murine oral keratinocytes. In vitro radiosensitization was tested by clonogenic assay. Cell cycle distribution and mitotic catastrophe were evaluated by flow cytometry. Mitotic aberrations were quantified by fluorescent microscopy. Tumor growth delay and survival were assessed in mice bearing MOC2 or JHU-012 transplant tumors treated with vehicle, ATRi, RT (10 Gy × 1 or 8 Gy × 3), or combined ATRi + RT. RESULTS: ATRi caused dose-dependent reduction in checkpoint kinase 1 phosphorylation at 1 hour post-RT (4 Gy) and dose-dependent increase in γH2AX at 18 hours post-RT. Addition of RT to ATRi led to decreased BAY 1895344 half-maximal inhibitory concentration in HNSCC cell lines but not in normal tissue surrogate immortalized murine oral keratinocytes. Clonogenic assays demonstrated radiosensitization in the HNSCC cell lines. ATRi abrogated the RT-induced G2/M checkpoint, leading to mitosis with unrepaired DNA damage and increased mitotic aberrations (multinucleated cells, micronuclei, nuclear buds, nucleoplasmic bridges). ATRi and RT significantly delayed tumor growth in MOC2 and JHU-012 in vivo models, with improved overall survival in the MOC2 model. CONCLUSIONS: These findings demonstrated that BAY 1895344 increased in vitro and in vivo radiosensitivity in HPV-negative HNSCC preclinical models, suggesting therapeutic potential warranting evaluation in clinical trials for patients with locally advanced or recurrent HPV-negative HNSCC.
引用
- Odhiambo DA, Pittman AN, Rickard AG, et al. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2023. PMID: 38104870. doi:10.1016/j.ijrobp.2023.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。